Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00079820
Other study ID # H-249-001
Secondary ID
Status Completed
Phase Phase 1
First received March 15, 2004
Last updated January 9, 2014
Start date April 2004
Est. completion date October 2006

Study information

Verified date January 2014
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to gather information on the safety and the effectiveness of an investigational vaccine for the prevention of smallpox disease. Smallpox was one of the major causes of death and sickness through the first half of the 20th century, but a global program of smallpox eradication resulted in the elimination of the natural disease. The last cases of smallpox in the United States occurred in 1949 in Texas. Today, only laboratory workers who work with smallpox-related viruses, military personnel, and health care workers are vaccinated.

Historically, individuals in the US were vaccinated with a product such as Dryvax®, which contains the virus vaccinia in the same family as smallpox. This virus could promote immunity to smallpox, but not produce the disease itself. Although effective, these vaccines are not safe to use in people with atopic dermatitis (eczema, allergic immune response to allergens), children less than 1 year of age, and people with a compromised immune system, occurring in certain diseases (HIV positive individuals and AIDS), and following treatment with certain types of drugs. It is important to find a safe vaccine that can be used to protect people who cannot receive routine vaccinia-based smallpox vaccine.

The vaccine in this study is known as Modified Vaccinia Ankara or MVA vaccine. It is the objective of this study to find out if MVA vaccine is safe and effective in providing immunity to smallpox. The effectiveness of this vaccine will be measured in two ways. The first way is to find out if there are specific antibodies in your blood following MVA vaccination. Antibodies are chemicals your body produces to fight smallpox virus.

The second way is to see whether or not there is a typical skin reaction following vaccination with a traditional smallpox vaccine, given about three months after vaccination with the MVA vaccine. The typical reaction in an unvaccinated person to smallpox vaccine is formation of a blister or "pox" which occurs at the site of vaccination. In a person with immunity to smallpox the skin reaction is much less, and typically consists of a little swelling at the site of vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date October 2006
Est. primary completion date October 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 31 Years
Eligibility Inclusion Criteria:

Subjects must meet the following to be eligible for the study:

- adult males or females who provided informed consent for the study.

- adults 18 and 31 years (inclusive).

- good general health,

- female subjects must not be pregnant or lactating and be on appropriate contraception or be a female unable to bear children.

- subjects be available for participation during the entire study.

Exclusion Criteria:

Any of the following exclusion criteria are met, the subject is NOT eligible.

- military service prior to 1989 or after December 13th, 2002.

- history of previous smallpox vaccination

- known/suspected history of immunodeficiency, or with current radiation treatment or use of immunosuppressive or anti-neoplastic drugs.

- subjects with a household member or intimate contact with the same conditions listed above.

- known or suspected impairment of other immunologic function.

- malignancy, including squamous cell or basal cell skin cancer at vaccination site

- active autoimmune disease.

- subjects with known eye diseases or other conditions that require the use of corticosteroid eye drops.

- known/history of cardiac disease.

- subjects who have been diagnosed with 3 or more of the following risk factors for ischemic coronary disease: a) high blood pressure b) elevated blood cholesterol levels c) diabetes or high blood sugar d) first degree relative (for example, mother, father, brother, or sister) who had a heart condition before the age of 50 e) smoke cigarettes

- subjects with a history of palpitations or abnormalities of cardiac rhythm.

- subjects with odd ECG patterns

- subjects with a ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years.

- positive or elevated creatinine kinase, CK-MB, or Troponin I laboratory test levels.

- abnormalities of clinical laboratory assessments.

- past history or current diagnosis of chronic renal disease, adverse reactions to drugs characterized by renal impairment, a serum creatinine > 1.5 mg/dL, or presence of 1+ protein in urinalysis at screening and a calculated creatinine clearance of not less than 80 mL/min.

- current diagnosis or past history of eczema.

- subjects with a household member or intimate contact with the same conditions listed above.

- presence of acute, chronic, or exfoliative skin conditions, open wounds, or burns.

- history of keloid formation.

- known allergies to MVA or to any known components (Neomycin, Gentamycin) of the vaccine.

- known allergy to eggs or egg products.

- known allergies to any component of the Dryvax® vaccine. Antibiotics in Dryvax® include neomycin, streptomycin, chlortetracycline, and polymixin B.

- known allergies to any known component of the Dryvax® diluent (i.e., glycerin and phenol).

- known allergies to any known component of VIG, (i.e., thimerosal or previous allergic reaction to immunoglobulins).

- known allergies to cidofovir or sulphur containing drugs, including probenecid, trimethoprim, and sulfonamide antibiotics.

- transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within 6 months of the screening visit.

- positive serology result for HIV, hepatitis B surface antigen, or hepatitis C.

- current diagnosis or history within six months of the screening visit of drug or alcohol abuse disorders.

- significant acute or chronic psychiatric illness.

- female subjects with a positive serum pregnancy test result

- subjects with a household member or direct contact with someone who is pregnant or lactating.

- temperature or acute illness within 3 days prior to vaccination

- inoculation with an inactivated vaccine with 14 days of Day 0 or with a live attenuated vaccine within 30 days of Day 0.

- subjects who have participated in another investigational drug or vaccine trial within 30 days of Day 0.

- subjects who are planning on donating blood or organs within 30 days of vaccination.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
ACAM3000 MVA Vaccine
Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days

Locations

Country Name City State
United States PRA International Lenexa Kansas
United States University of Kentucky Medical Center Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Study Completion Yes
Secondary Immunogenicity Study Completion No
See also
  Status Clinical Trial Phase
Completed NCT05976100 - Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years Phase 1
Completed NCT01540929 - Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
Completed NCT00258947 - Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Phase 2
Completed NCT00189969 - Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects Phase 1
Terminated NCT00053508 - Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Phase 2
Completed NCT01317238 - Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Phase 3
Completed NCT01056770 - Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Phase 3
Completed NCT00998543 - A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) Phase 2
Withdrawn NCT00389103 - Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) Phase 1
Terminated NCT00282581 - Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive Phase 1
Completed NCT00133575 - ACAM 3000 MVA at Harvard Medical School Phase 1/Phase 2
Active, not recruiting NCT00103584 - Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Phase 1/Phase 2
Completed NCT00050505 - Expanded Dryvax Dilution Study in Previously Vaccinated Adults Phase 2
Completed NCT05846243 - Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years Phase 2/Phase 3
Completed NCT05935917 - Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults Phase 1
Completed NCT00082446 - Combination Study With MVA BN and Dryvax Phase 1
Completed NCT00038987 - Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Phase 1/Phase 2
Completed NCT05762523 - Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years Phase 1
Completed NCT04971109 - Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day Phase 3
Completed NCT00646152 - Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study Phase 1